Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial
ABSTRACT Objective: Carpometacarpal osteoarthritis (CMC OA) is highly prevalent in older adults, and is often unresponsive to medical treatment. Intra-articular Hylan G-F 20 has been shown to improve pain and function in patients with knee OA; however, its effectiveness in CMC OA is less clear. Meth...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 2009-09, Vol.25 (9), p.2103-2108 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2108 |
|---|---|
| container_issue | 9 |
| container_start_page | 2103 |
| container_title | Current medical research and opinion |
| container_volume | 25 |
| creator | Mandl, Lisa A. Hotchkiss, Robert N. Adler, Ronald S. Lyman, Stephen Daluiski, Aaron Wolfe, Scott W. Katz, Jeffrey N. |
| description | ABSTRACT
Objective: Carpometacarpal osteoarthritis (CMC OA) is highly prevalent in older adults, and is often unresponsive to medical treatment. Intra-articular Hylan G-F 20 has been shown to improve pain and function in patients with knee OA; however, its effectiveness in CMC OA is less clear.
Methods: 32 patients with CMC OA were injected with Hylan G-F 20, once weekly for three consecutive weeks. Patients were assessed 4, 12, 20 and 26 weeks after the first injection. A last-value carried forward analysis was performed.
Results: Average age was 64 years, (range 46-79), 69% were female and 97% Caucasian. Fifty-three percent had at least one previous corticosteroid injection in the affected CMC joint. At 26 weeks, mean visual analogue scale (VAS) for pain had improved significantly (15.2 mm; p-value = 0.006). Disabilities of the arm, shoulder and hand questionnaire (DASH) scores also improved significantly (12.6; p-value |
| doi_str_mv | 10.1185/03007990903084016 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2761209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19601706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-b0afd6c0395eeb2b78abe6998430c83e6294420fcb5a9fe4033486a9c310b7f63</originalsourceid><addsrcrecordid>eNp9kN1q3DAQRkVpaLZpH6A3RS_gdmTZstWWQgj9CQRyk1yLsXZUa5EtI2tb9u2rZUPbUMiVBuY7n4bD2BsB74To2_cgATqtQZehb0CoZ2wjmk5WTd91z9nmuK9KoD1nL9d1ByDqXusX7FxoBaIDtWF4Pe_IZhwC8fGAYZ_ijDN3MfE8Es-JME80Zx4dt5iWOFHG44CBxzVTxJTH5LNfP_C40MwDDhT44kPMhfYYXrEzh2Gl1w_vBbv_-uXu6nt1c_vt-uryprItyFwNgG6rLEjdEg310PWlSGndNxJsL0nVumlqcHZoUTtqQMqmV6itFDB0TskL9vnUu-yHiba2HJ0wmCX5CdPBRPTm8Wb2o_kRf5q6U6IGXQrEqcCmuK6J3B9WgDn6Nv_5Lszbfz_9SzwILoFPp4Cfi9MJf8UUtibjIcTkEs7Wr0Y-1f_xET4ShjwW_2R2cZ_mIvSJ634D2eijsQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Mandl, Lisa A. ; Hotchkiss, Robert N. ; Adler, Ronald S. ; Lyman, Stephen ; Daluiski, Aaron ; Wolfe, Scott W. ; Katz, Jeffrey N.</creator><creatorcontrib>Mandl, Lisa A. ; Hotchkiss, Robert N. ; Adler, Ronald S. ; Lyman, Stephen ; Daluiski, Aaron ; Wolfe, Scott W. ; Katz, Jeffrey N.</creatorcontrib><description>ABSTRACT
Objective: Carpometacarpal osteoarthritis (CMC OA) is highly prevalent in older adults, and is often unresponsive to medical treatment. Intra-articular Hylan G-F 20 has been shown to improve pain and function in patients with knee OA; however, its effectiveness in CMC OA is less clear.
Methods: 32 patients with CMC OA were injected with Hylan G-F 20, once weekly for three consecutive weeks. Patients were assessed 4, 12, 20 and 26 weeks after the first injection. A last-value carried forward analysis was performed.
Results: Average age was 64 years, (range 46-79), 69% were female and 97% Caucasian. Fifty-three percent had at least one previous corticosteroid injection in the affected CMC joint. At 26 weeks, mean visual analogue scale (VAS) for pain had improved significantly (15.2 mm; p-value = 0.006). Disabilities of the arm, shoulder and hand questionnaire (DASH) scores also improved significantly (12.6; p-value < 0.001). A DASH change of 10-14 is considered clinically meaningful. Neither key strength nor opposition grip strength improved. VAS scores for pain at 26 weeks showed good correlation with patient satisfaction (Spearman r = 0.52, p-value < 0.01). Adverse events potentially related to the injections included three episodes of post-injection pain and swelling, and one case of crystal proven pseudogout.
Conclusion: Intra-articular Hylan G-F 20 injections reduced pain and improved function in patients with CMC OA at 26 weeks in this small open label study. Limitations of this study include its small, open label design. Larger randomized controlled trials are needed to confirm these results, and to determine predictors of response to treatment.
Clinical trial registration: This study was approved by the Institutional Review Board at the Hospital for Special Surgery, New York, NY, USA and registered at www.clinicatrials.gov # NCT00198029.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007990903084016</identifier><identifier>PMID: 19601706</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - adverse effects ; Aged ; Carpometacarpal joint ; Carpometacarpal Joints - drug effects ; Carpometacarpal Joints - pathology ; Edema - epidemiology ; Edema - etiology ; Female ; Hand Strength ; Humans ; Hyaluronan ; Hyaluronic Acid - administration & dosage ; Hyaluronic Acid - adverse effects ; Injections, Intra-Articular ; Male ; Middle Aged ; Osteoarthritis ; Osteoarthritis - drug therapy ; Osteoarthritis - pathology ; Pain - epidemiology ; Pain - etiology ; Patient Satisfaction ; Pilot Projects</subject><ispartof>Current medical research and opinion, 2009-09, Vol.25 (9), p.2103-2108</ispartof><rights>2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-b0afd6c0395eeb2b78abe6998430c83e6294420fcb5a9fe4033486a9c310b7f63</citedby><cites>FETCH-LOGICAL-c503t-b0afd6c0395eeb2b78abe6998430c83e6294420fcb5a9fe4033486a9c310b7f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/03007990903084016$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/03007990903084016$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,59623,59729,60412,60518,61197,61232,61378,61413</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19601706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mandl, Lisa A.</creatorcontrib><creatorcontrib>Hotchkiss, Robert N.</creatorcontrib><creatorcontrib>Adler, Ronald S.</creatorcontrib><creatorcontrib>Lyman, Stephen</creatorcontrib><creatorcontrib>Daluiski, Aaron</creatorcontrib><creatorcontrib>Wolfe, Scott W.</creatorcontrib><creatorcontrib>Katz, Jeffrey N.</creatorcontrib><title>Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT
Objective: Carpometacarpal osteoarthritis (CMC OA) is highly prevalent in older adults, and is often unresponsive to medical treatment. Intra-articular Hylan G-F 20 has been shown to improve pain and function in patients with knee OA; however, its effectiveness in CMC OA is less clear.
Methods: 32 patients with CMC OA were injected with Hylan G-F 20, once weekly for three consecutive weeks. Patients were assessed 4, 12, 20 and 26 weeks after the first injection. A last-value carried forward analysis was performed.
Results: Average age was 64 years, (range 46-79), 69% were female and 97% Caucasian. Fifty-three percent had at least one previous corticosteroid injection in the affected CMC joint. At 26 weeks, mean visual analogue scale (VAS) for pain had improved significantly (15.2 mm; p-value = 0.006). Disabilities of the arm, shoulder and hand questionnaire (DASH) scores also improved significantly (12.6; p-value < 0.001). A DASH change of 10-14 is considered clinically meaningful. Neither key strength nor opposition grip strength improved. VAS scores for pain at 26 weeks showed good correlation with patient satisfaction (Spearman r = 0.52, p-value < 0.01). Adverse events potentially related to the injections included three episodes of post-injection pain and swelling, and one case of crystal proven pseudogout.
Conclusion: Intra-articular Hylan G-F 20 injections reduced pain and improved function in patients with CMC OA at 26 weeks in this small open label study. Limitations of this study include its small, open label design. Larger randomized controlled trials are needed to confirm these results, and to determine predictors of response to treatment.
Clinical trial registration: This study was approved by the Institutional Review Board at the Hospital for Special Surgery, New York, NY, USA and registered at www.clinicatrials.gov # NCT00198029.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adjuvants, Immunologic - adverse effects</subject><subject>Aged</subject><subject>Carpometacarpal joint</subject><subject>Carpometacarpal Joints - drug effects</subject><subject>Carpometacarpal Joints - pathology</subject><subject>Edema - epidemiology</subject><subject>Edema - etiology</subject><subject>Female</subject><subject>Hand Strength</subject><subject>Humans</subject><subject>Hyaluronan</subject><subject>Hyaluronic Acid - administration & dosage</subject><subject>Hyaluronic Acid - adverse effects</subject><subject>Injections, Intra-Articular</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Osteoarthritis - pathology</subject><subject>Pain - epidemiology</subject><subject>Pain - etiology</subject><subject>Patient Satisfaction</subject><subject>Pilot Projects</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1q3DAQRkVpaLZpH6A3RS_gdmTZstWWQgj9CQRyk1yLsXZUa5EtI2tb9u2rZUPbUMiVBuY7n4bD2BsB74To2_cgATqtQZehb0CoZ2wjmk5WTd91z9nmuK9KoD1nL9d1ByDqXusX7FxoBaIDtWF4Pe_IZhwC8fGAYZ_ijDN3MfE8Es-JME80Zx4dt5iWOFHG44CBxzVTxJTH5LNfP_C40MwDDhT44kPMhfYYXrEzh2Gl1w_vBbv_-uXu6nt1c_vt-uryprItyFwNgG6rLEjdEg310PWlSGndNxJsL0nVumlqcHZoUTtqQMqmV6itFDB0TskL9vnUu-yHiba2HJ0wmCX5CdPBRPTm8Wb2o_kRf5q6U6IGXQrEqcCmuK6J3B9WgDn6Nv_5Lszbfz_9SzwILoFPp4Cfi9MJf8UUtibjIcTkEs7Wr0Y-1f_xET4ShjwW_2R2cZ_mIvSJ634D2eijsQ</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Mandl, Lisa A.</creator><creator>Hotchkiss, Robert N.</creator><creator>Adler, Ronald S.</creator><creator>Lyman, Stephen</creator><creator>Daluiski, Aaron</creator><creator>Wolfe, Scott W.</creator><creator>Katz, Jeffrey N.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>200909</creationdate><title>Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial</title><author>Mandl, Lisa A. ; Hotchkiss, Robert N. ; Adler, Ronald S. ; Lyman, Stephen ; Daluiski, Aaron ; Wolfe, Scott W. ; Katz, Jeffrey N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-b0afd6c0395eeb2b78abe6998430c83e6294420fcb5a9fe4033486a9c310b7f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adjuvants, Immunologic - adverse effects</topic><topic>Aged</topic><topic>Carpometacarpal joint</topic><topic>Carpometacarpal Joints - drug effects</topic><topic>Carpometacarpal Joints - pathology</topic><topic>Edema - epidemiology</topic><topic>Edema - etiology</topic><topic>Female</topic><topic>Hand Strength</topic><topic>Humans</topic><topic>Hyaluronan</topic><topic>Hyaluronic Acid - administration & dosage</topic><topic>Hyaluronic Acid - adverse effects</topic><topic>Injections, Intra-Articular</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Osteoarthritis - pathology</topic><topic>Pain - epidemiology</topic><topic>Pain - etiology</topic><topic>Patient Satisfaction</topic><topic>Pilot Projects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mandl, Lisa A.</creatorcontrib><creatorcontrib>Hotchkiss, Robert N.</creatorcontrib><creatorcontrib>Adler, Ronald S.</creatorcontrib><creatorcontrib>Lyman, Stephen</creatorcontrib><creatorcontrib>Daluiski, Aaron</creatorcontrib><creatorcontrib>Wolfe, Scott W.</creatorcontrib><creatorcontrib>Katz, Jeffrey N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mandl, Lisa A.</au><au>Hotchkiss, Robert N.</au><au>Adler, Ronald S.</au><au>Lyman, Stephen</au><au>Daluiski, Aaron</au><au>Wolfe, Scott W.</au><au>Katz, Jeffrey N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2009-09</date><risdate>2009</risdate><volume>25</volume><issue>9</issue><spage>2103</spage><epage>2108</epage><pages>2103-2108</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>ABSTRACT
Objective: Carpometacarpal osteoarthritis (CMC OA) is highly prevalent in older adults, and is often unresponsive to medical treatment. Intra-articular Hylan G-F 20 has been shown to improve pain and function in patients with knee OA; however, its effectiveness in CMC OA is less clear.
Methods: 32 patients with CMC OA were injected with Hylan G-F 20, once weekly for three consecutive weeks. Patients were assessed 4, 12, 20 and 26 weeks after the first injection. A last-value carried forward analysis was performed.
Results: Average age was 64 years, (range 46-79), 69% were female and 97% Caucasian. Fifty-three percent had at least one previous corticosteroid injection in the affected CMC joint. At 26 weeks, mean visual analogue scale (VAS) for pain had improved significantly (15.2 mm; p-value = 0.006). Disabilities of the arm, shoulder and hand questionnaire (DASH) scores also improved significantly (12.6; p-value < 0.001). A DASH change of 10-14 is considered clinically meaningful. Neither key strength nor opposition grip strength improved. VAS scores for pain at 26 weeks showed good correlation with patient satisfaction (Spearman r = 0.52, p-value < 0.01). Adverse events potentially related to the injections included three episodes of post-injection pain and swelling, and one case of crystal proven pseudogout.
Conclusion: Intra-articular Hylan G-F 20 injections reduced pain and improved function in patients with CMC OA at 26 weeks in this small open label study. Limitations of this study include its small, open label design. Larger randomized controlled trials are needed to confirm these results, and to determine predictors of response to treatment.
Clinical trial registration: This study was approved by the Institutional Review Board at the Hospital for Special Surgery, New York, NY, USA and registered at www.clinicatrials.gov # NCT00198029.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19601706</pmid><doi>10.1185/03007990903084016</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2009-09, Vol.25 (9), p.2103-2108 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2761209 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - adverse effects Aged Carpometacarpal joint Carpometacarpal Joints - drug effects Carpometacarpal Joints - pathology Edema - epidemiology Edema - etiology Female Hand Strength Humans Hyaluronan Hyaluronic Acid - administration & dosage Hyaluronic Acid - adverse effects Injections, Intra-Articular Male Middle Aged Osteoarthritis Osteoarthritis - drug therapy Osteoarthritis - pathology Pain - epidemiology Pain - etiology Patient Satisfaction Pilot Projects |
| title | Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A38%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Injectable%20hyaluronan%20for%20the%20treatment%20of%20carpometacarpal%20osteoarthritis:%20open%20label%20pilot%20trial&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Mandl,%20Lisa%20A.&rft.date=2009-09&rft.volume=25&rft.issue=9&rft.spage=2103&rft.epage=2108&rft.pages=2103-2108&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1185/03007990903084016&rft_dat=%3Cpubmed_infor%3E19601706%3C/pubmed_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19601706&rfr_iscdi=true |